Blau Farmacêutica 4Q25 slides: margin gains offset revenue miss
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Brent nears $110/bbl after attack on world’s largest natural gas field in Iran Gold prices extend decline as rate uncertainty grows before Fed meeting Up 31%+, this AI-picked energy infrastructure play is a Middle East conflict win Global stocks could fall 30% in extended conflict scenario, UBS warns FLASH SALE (South Africa Philippines Nigeria) FLASH SALE Blau Farmacêutica 4Q25 slides: margin gains offset revenue miss By Company News Published 03/18/2026, 11:38 AM Blau Farmacêutica 4Q25 slides: margin gains offset revenue miss 0 BLAU3 -2.70% Introduction & Market Context Blau Farmacêutica SA (BVMF:BLAU3) presented its fourth-quarter and full-year 2025 results on March 18, 2026, revealing a challenging quarter that significantly missed analyst expectations despite continued operational improvements. The Brazilian pharmaceutical company’s stock fell 3.9% to BRL 10.01 following the presentation, extending losses from the initial 5.09% after-hours decline when results were first announced. The company reported Q4 2025 revenue of BRL 389 million, representing a 19.68% miss against the BRL 484.34 million analyst consensus and a 14.7% decline from the prior-year quarter. Earnings per share of BRL 0.2308 fell 15.86% short of the BRL 0.2743 forecast, underscoring the impact of federal bidding delays and production capacity constraints that weighed on the quarter. Executive Summary: Full Year 2025 Performance Despite the difficult fourth quarter, Blau’s full-year 2025 results demonstrated significant operational progress, with the company achieving record profitability and shareholder returns while navigating revenue headwinds. As shown in the following overview of annual highlights, the company delivered net revenue of BRL 1.7 billion, down 3% year-over-year, while simultaneously expanding gross margins by 260 basis points to 40% and increasing net income by 39% to BRL 297 million. The company’s strategic accomplishm...
Read full article at source